There is a relative paucity of data on the morbidity/mortality associated with bacterial pneumonia in the era of GSI-IX potent cART in those with higher CD4 cell counts, although several cohort studies have indicated declining rates of morbidity and mortality associated with cART use and, in some studies, pneumococcal polysaccharide vaccine (PPV-23) [9–11]. In a Danish study exploring

the risks for hospitalization with pneumonia (including viral pneumonia but excluding PcP), HIV-1-infected patients with a nadir CD4 count >300 cells/μL had a rate of bacterial pneumonia of 1.25 per 100 PY [5]. In the Strategies for Management of Anti-Retroviral Therapy (SMART) study, which enrolled participants with baseline CD4 count ≥350 cells/μL [12], patients on continuous

cART had a rate of bacterial pneumonia of 1.3 per 100 PY. The clinical benefits of intermittent recombinant interleukin-2 (rIL-2) in HIV-1-infected adults on cART have been explored in two major Phase III international studies. In Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT), HIV-1-infected adults on or starting cART, with CD4 count ≥300 cells/μL, were randomized to intermittent rIL-2 with http://www.selleckchem.com/products/jq1.html cART (IL-2 arm) or cART alone (control arm or non-IL-2 arm) [13]. The primary endpoints, ADI and death, were reported in both study arms for the duration of follow-up. The main results of ESPRIT have been reported [14]. In summary, the receipt of rIL-2 conferred no clinical benefit with respect to ADI and all-cause mortality despite a significant

difference in CD4 count compared with the control arm, with CD4 count averaged over follow-up being 159 cells/μL [95% confidence interval (CI) 145–174 cells/μL; P<0.001] higher in the IL-2 arm than in the control arm. Recombinant IL-2 used in the oncology and/or HIV setting [15] has been associated with an increased risk of some bacterial infections, including cellulitis, osteomyelitis, Clostridium difficile infection [16], bacteraemia and bacterial pneumonia; the mechanism of the association www.selleck.co.jp/products/s-gsk1349572.html is unclear. The ESPRIT cohort offered an opportunity to explore both the rate of bacterial pneumonia over several years (≈7 years) in a large cohort of cART-treated HIV-1-infected adults with moderate levels of immunodeficiency and the relationship between rIL-2 exposure and bacterial pneumonia. The methods [13] and main results [14] of ESPRIT have been reported previously. Key inclusion criteria included CD4 count ≥300 cells/μL and on/commencing cART. Centers for Disease Control category C patients could be enrolled provided that there was no active ADI for ≥12 months. Patients randomized to the IL-2 arm received three dosing cycles of rIL-2 [7.5 MIU subcutaneously twice a day for five consecutive days every 8 weeks] as induction in year 1.